Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
REMUNE FULL PRESCRIBING
REMUNEX Vaccine
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Vaccines Direct
Partnering
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map
Immune Response BioPharma, Inc. TM        Copyright (c) 2010-2017  

RAVAXX II TM   Next Generation Rheumatoid Arthritis Vaccine 


RAVAXX II TM  IR-555 Next Generation RA Vaccine           www.ravax.org 
Pre-Clinical TCR Peptides BV3, BV12, BV14, & BV17 Formulation
01/10/2014 U.S. Non Provisional Patent Application Filing #14152947 
                   TCR Peptides Vaccination & Methods Against RA Rheumatoid Arthritis
                                                        
Rheumatoid Arthritis is a chronic long term disease and a form of inflammatory arthritis known as an autoimmune disease. In RA, for reasons no one fully understands, the immune system – which is designed to protect our health by attacking foreign cells such as viruses and bacteria – instead attacks the body’s own tissues, specifically the synovium, a thin membrane that lines the joints. As a result of the attack, fluid builds up in the joints, causing pain in the joints and inflammation that’s systemic – meaning it can occur throughout the body. RA is a chronic disease that causes pain, stiffness, swelling and limited motion and function of many joints. While RA can affect any joint, the small joints in the hands and feet tend to be involved most often. Inflammation sometimes can affect organs as well, for instance, the eyes or lungs.
Rheumatoid Arthritis – 2.1 million + patients in the U.S.– 3-4% of the global population 75% of Patients are Women










Immune Response BioPharma, Inc. TM         
Copyright (c) 2010-2017 All Rights Reseved www.immuneresponse.net